Page last updated: 2024-09-05

orantinib and Carcinoma, Epidermoid

orantinib has been researched along with Carcinoma, Epidermoid in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (75.00)	29.6817
2010's	1 (25.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Hokoda, N; Kasahara, K; Kitamura, R; Miyazaki, M; Nakagawa, K; Nakayama, H; Ohyama, A; Okamoto, I; Satouchi, M; Seto, T; Takeda, K; Yamamoto, N; Yoshihara, E; Yoshioka, H	1
Bruns, CJ; Guba, M; Jauch, KW; Kleespies, A	1
Kitagawa, Y; Kitajima, M; Kubota, T; Nakamura, T; Ozawa, S; Ueda, M	1
Cherrington, JM; Knox, SJ; Laird, D; Ning, S	1

Reviews

1 review(s) available for orantinib and Carcinoma, Epidermoid

Article	Year
Vascular endothelial growth factor in esophageal cancer. Journal of surgical oncology, 2004, Aug-01, Volume: 87, Issue:2 Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Barrett Esophagus; Bevacizumab; Carcinoma, Squamous Cell; Esophageal Neoplasms; Humans; Indoles; Lymphangiogenesis; Neovascularization, Pathologic; Oxindoles; Prognosis; Propionates; Protein-Tyrosine Kinases; Pyrroles; RNA, Catalytic; RNA, Messenger; Vascular Endothelial Growth Factor A	2004

Article

Year

Vascular endothelial growth factor in esophageal cancer.

Journal of surgical oncology, 2004, Aug-01, Volume: 87, Issue:2

Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Barrett Esophagus; Bevacizumab; Carcinoma, Squamous Cell; Esophageal Neoplasms; Humans; Indoles; Lymphangiogenesis; Neovascularization, Pathologic; Oxindoles; Prognosis; Propionates; Protein-Tyrosine Kinases; Pyrroles; RNA, Catalytic; RNA, Messenger; Vascular Endothelial Growth Factor A

2004

Trials

1 trial(s) available for orantinib and Carcinoma, Epidermoid

Article	Year
Phase I clinical study of the angiogenesis inhibitor TSU-68 combined with carboplatin and paclitaxel in chemotherapy-naive patients with advanced non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2012, Volume: 7, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Feasibility Studies; Female; Follow-Up Studies; Humans; Indoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Oxindoles; Paclitaxel; Propionates; Pyrroles; Tissue Distribution; Treatment Outcome; Young Adult	2012

Article

Year

Phase I clinical study of the angiogenesis inhibitor TSU-68 combined with carboplatin and paclitaxel in chemotherapy-naive patients with advanced non-small cell lung cancer.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2012, Volume: 7, Issue:2

Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Feasibility Studies; Female; Follow-Up Studies; Humans; Indoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Oxindoles; Paclitaxel; Propionates; Pyrroles; Tissue Distribution; Treatment Outcome; Young Adult

2012

Other Studies

2 other study(ies) available for orantinib and Carcinoma, Epidermoid

Article	Year
Antiangiogenic agent SU6668 suppresses the tumor growth of xenografted A-431 cells. Oncology reports, 2006, Volume: 15, Issue:1 Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Squamous Cell; Endothelium, Vascular; Esophageal Neoplasms; Humans; Indoles; Mice; Mice, SCID; Neoplasm Transplantation; Neovascularization, Pathologic; Oxindoles; Platelet Endothelial Cell Adhesion Molecule-1; Propionates; Pyrroles; Xenograft Model Antitumor Assays	2006
The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation. Radiation research, 2002, Volume: 157, Issue:1 Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Dose Fractionation, Radiation; Drug Screening Assays, Antitumor; Endothelial Growth Factors; Fibroblast Growth Factor 2; Gene Expression Regulation, Neoplastic; Indoles; Lymphokines; Mice; Mice, Inbred C3H; Neoplasm Proteins; Oxindoles; Platelet-Derived Growth Factor; Propionates; Pyrroles; Radiation-Sensitizing Agents; Radioisotope Teletherapy; Receptor Protein-Tyrosine Kinases; Receptors, Fibroblast Growth Factor; Receptors, Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; RNA, Messenger; RNA, Neoplasm; Specific Pathogen-Free Organisms; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors	2002

Article

Year

Antiangiogenic agent SU6668 suppresses the tumor growth of xenografted A-431 cells.

Oncology reports, 2006, Volume: 15, Issue:1

Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Squamous Cell; Endothelium, Vascular; Esophageal Neoplasms; Humans; Indoles; Mice; Mice, SCID; Neoplasm Transplantation; Neovascularization, Pathologic; Oxindoles; Platelet Endothelial Cell Adhesion Molecule-1; Propionates; Pyrroles; Xenograft Model Antitumor Assays

2006

The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation.

Radiation research, 2002, Volume: 157, Issue:1

Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Dose Fractionation, Radiation; Drug Screening Assays, Antitumor; Endothelial Growth Factors; Fibroblast Growth Factor 2; Gene Expression Regulation, Neoplastic; Indoles; Lymphokines; Mice; Mice, Inbred C3H; Neoplasm Proteins; Oxindoles; Platelet-Derived Growth Factor; Propionates; Pyrroles; Radiation-Sensitizing Agents; Radioisotope Teletherapy; Receptor Protein-Tyrosine Kinases; Receptors, Fibroblast Growth Factor; Receptors, Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; RNA, Messenger; RNA, Neoplasm; Specific Pathogen-Free Organisms; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors

2002